Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1427570 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.99Day +0.00%Mkt cap $14MOff 52W high −87.6%Vol (1Y) 96.7%
Daily closing price, split-adjusted to the current basis; 0.9y shown of 229 bars on file. Sampled to 229 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.6% of sh out |
| Days to cover2.1d |
| 13F net flow (QoQ)+0.46% |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$319,714 |
| Earnings (TTM)-$10.9M |
| Net margin−3209.7% |
| Sales growth 3Y−69.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−42.2% |
Total return through 2026-07-29 · series begins 2025-08-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)96.7% |
| Ann. volatility (3Y)96.7% |
| Sharpe (1Y)−1.72 |
| Sharpe (3Y)−1.72 |
| Max drawdown (1Y)−86.5% |
| Max drawdown (3Y)−86.5% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 25,793 | $55,454 | 0.37% | +116.1% |
| UBS Group AG | 22,675 | $48,751 | 0.32% | +472.7% |
| Focus Partners Wealth | 14,640 | $31,476 | 0.21% | +0.0% |
| VANGUARD FIDUCIARY TRUST CO | 12,195 | $26,219 | 0.17% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 9,463 | $20,345 | 0.13% | new |
| ROYAL BANK OF CANADA | 5,856 | $13,000 | 0.08% | +0.0% |
| Tower Research Capital LLC (TRC) | 1,391 | $2,991 | 0.02% | new |
| CITIGROUP INC | 16 | $34 | 0.00% | +1500.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.15 | — | $31,591 | −84.1% |
| 2025-09-30 | 2025-11-14 | −$3.12 | — | $34,627 | −59.0% |
| 2025-06-30 | 2025-08-14 | — | — | $1.2M | −36.8% |
| 2025-03-31 | 2025-05-20 | — | — | $198,581 | −89.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
Pharmaceutical 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
